MEETING OF COMMISSION OF INTELLECTUAL PROPERTY RIGHTS, INNOVATION & PUBLIC HEALTH
INTELLECTUAL PROPERTY SYSTEM AND ACCESS TO HEALTHCARE

INNOVATION

PRODUCT → IPR

PUBLIC HEALTH

A Need for Fair and affordable access to healthcare for all
SHANTHA BIOTECHNICS LTD.

(ESTABLISHED: 1993)

- Initiated based on perceived gap between the need and availability of rDNA technology based drugs
- With a commitment to supply quality products at affordable cost
- While developing technologies for Hepatitis B vaccine and Interferon, focused on acquiring the expertise essential for this specialty area and building infrastructure and manufacturing capabilities.

Established ourselves and rDNA based Biotechnology in India.
Shantha’s Approach
Towards Product Development

- Consciously try to innovate even in the development of off patented products

- Committed to take up innovative research alone or in collaboration with national laboratories
PHASE-I

DEVELOPMENT OF GENERIC PRODUCTS
LIST OF PRODUCTS

- **SHANVAC B**: recombinant hepatitis B Vaccine
  
  IPR status: Expired
  
  Innovation: Two Indian patents on novel aspects of the purification process

- **SHANFERON**: recombinant Interferon alpha 2b
  
  IPR status: Expired in 2002
  
  Innovation: PCT publication on the novel process used for its production and filing underway in several countries

*Pichia pastoris, the novel host system used for the production of these products is being used under a license from RCT Inc., USA*
SHANKINASE: recombinant Streptokinase

IPR issue : Process patent/s

Innovation : A novel purification process

SHANPOIETIN: recombinant Erythropoietin

IPR issue: expiry in 2005

Innovation : A novel purification process
Recombinant human GCSF

(Product patent expires in 2006)

Developing a product in a novel host and by a novel process different from the one used for the existing product (filgrastim), though we could have copied it and commercialize by now.
PHASE-II

DEVELOPMENT OF NOVEL PRODUCTS

- Exploration of the possibility of making patentable improved inventions on the basis of patent of others.

- Initiation of Discovery Programmes:
  - Oral Cancer
  - Development of Anti-Malarial drug (IISC Bangalore)
  - Mapping of Signal Transduction Pathways in order to identify novel targets amenable to therapy under different disease settings (ICGEB).
Strive constantly to increase our product portfolio by own development, collaboration or through licensing, while continuing to be committed to provide cost effective drugs.

Expect Government intervention whenever the Interest of the Inventor overrides the Interest of the public. We feel this may be necessary not only in the management of pandemics like AIDS/HIV, but also in several other circumstances.